Technology | August 29, 2013

Bayer Launches New Jetstream XC and SC Atherectomy Catheters

The catheters can be used to treat PAD and multiple lesion morphologies

August 29, 2013 — Bayer HealthCare announced that the U.S. Food and Drug Administration (FDA) has cleared two new Jetstream atherectomy catheters. The SC (Single Cutter) atherectomy catheter is available in 1.6-mm and 1.85-mm cutting diameters.  The XC (eXpandable cutter) atherectomy catheter features both front cutting tip and expandable blade technology for use in larger vessels.  The XC is available in two cutting diameters: 2.1-mm blades down / 3.0-mm blades up and 2.4-mm blades down / 3.4-mm blades up.

Redesigned, integrated control pods feature:

  • Ergonomic design and smaller size (32 percent) for improved ease of use
  • New user interface to facilitate single or dual operator use 
  • Simplified guidewire management through improved wire GARD
  • Reduced storage space requirements and environmental impact through new control pod design and improved packaging

 

The Jetstream Atherectomy System is one of the most versatile debulking solutions for the treatment of peripheral artery disease (PAD).  The system catheters can be used to treat multiple lesion morphologies – from thrombus to the most challenging calcium deposits. Catheters are available in both SC and XC sizes to support treatment of vessels above and below the knee. The Jetstream System consists of a single-use catheter with control pod and a reusable, compact console that mounts to a standard IV stand. 

For more information: www.ri.bayer.com

Related Content

People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. 

Feature | Cath Lab | October 03, 2019
October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with pe
Two Stents Implanted in Democratic Presidential Candidate Bernie Sanders, suffers chest pain
News | Cath Lab | October 02, 2019 | Dave Fornell, Editor
October 2, 2019 — Democratic presidential candidate Sen.
Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival
News | Cath Lab | September 25, 2019
Ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting stents in randomized...
Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
FDA Grants Shockwave Medical Breakthrough Status for Coronary Intravascular Lithotripsy
News | Cath Lab | September 03, 2019
Shockwave Medical Inc. has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA)...
Compound Could Help Improve Heart Attack Recovery
News | Cath Lab | August 27, 2019
Imagine there were a drug that you could take soon after a heart attack that could reduce damage by protecting healthy...
New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019
VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter...
Overlay Init